Literature DB >> 10713063

Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor.

V Rajagopal1, R J Kreitman.   

Abstract

The alpha(2-)macroglobulin receptor (alpha(2)MR) has been reported to mediate the internalization of the urokinase plasminogen activator receptor (uPAR) via ligand binding to both receptors. To target malignant uPAR-expressing cells and to determine whether uPAR can internalize without ligand binding to alpha(2)MR, we engineered two recombinant toxins, ATF-PE38 and ATF-PE38KDEL. Each consists of the amino-terminal fragment (ATF) of human urokinase and a truncated form of Pseudomonas exotoxin (PE) devoid of domain Ia, which binds alpha(2)MR. ATF-PE38 and ATF-PE38KDEL were cytotoxic toward malignant uPAR-bearing cells, with IC(50) values as low as 0.02 ng/ml (0.3 pM). Cytotoxicity could be blocked using either recombinant urokinase or free ATF, indicating that the cytotoxicity of the recombinant toxins was specific. Radiolabeled ATF-PE38 had high affinity for uPAR (K(d) = 0.4-8 nM) on a variety of different malignant cell types and internalized at a rate similar to that of ATF. The cytotoxicity was not diminished by receptor-associated protein, which binds and shields the alpha(2)MR from other proteins, or by incubation with phorbol myristate acetate, which is known to decrease the number of alpha(2)MRs in U937 cells or by antibodies to alpha(2)MR. Therefore, these recombinant toxins appear to internalize via uPAR without association with the alpha(2)MR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713063     DOI: 10.1074/jbc.275.11.7566

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  18 in total

1.  Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.

Authors:  Young C Shin; William R Folk
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

3.  Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.

Authors:  Ying Xiang; Qiying Li; Dehong Huang; Xianjun Tang; Li Wang; Yang Shi; Wenjun Zhang; Tao Yang; Chunyan Xiao; Jianghong Wang
Journal:  Exp Biol Med (Maywood)       Date:  2014-08-14

4.  Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.

Authors:  Andrew P Mazar; Richard W Ahn; Thomas V O'Halloran
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

5.  Reprogramming urokinase into an antibody-recruiting anticancer agent.

Authors:  Charles E Jakobsche; Patrick J McEnaney; Andrew X Zhang; David A Spiegel
Journal:  ACS Chem Biol       Date:  2011-11-18       Impact factor: 5.100

6.  Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.

Authors:  Lily Yang; Hui Mao; Zehong Cao; Y Andrew Wang; Xianghong Peng; Xiaoxia Wang; Hari K Sajja; Liya Wang; Hongwei Duan; Chunchun Ni; Charles A Staley; William C Wood; Xiaohu Gao; Shuming Nie
Journal:  Gastroenterology       Date:  2009-01-14       Impact factor: 22.682

7.  Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.

Authors:  Gee Young Lee; Wei Ping Qian; Liya Wang; Yongqiang Andrew Wang; Charles A Staley; Minati Satpathy; Shuming Nie; Hui Mao; Lily Yang
Journal:  ACS Nano       Date:  2013-03-12       Impact factor: 15.881

8.  Receptor-targeted nanoparticles for in vivo imaging of breast cancer.

Authors:  Lily Yang; Xiang-Hong Peng; Y Andrew Wang; Xiaoxia Wang; Zehong Cao; Chunchun Ni; Prasanthi Karna; Xinjian Zhang; William C Wood; Xiaohu Gao; Shuming Nie; Hui Mao
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

Review 9.  Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.

Authors:  Niaz Mahmood; Shafaat A Rabbani
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 10.  Ribosome-inactivating proteins: from plant defense to tumor attack.

Authors:  Maddalena de Virgilio; Alessio Lombardi; Rocco Caliandro; Maria Serena Fabbrini
Journal:  Toxins (Basel)       Date:  2010-11-10       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.